賽升藥業(300485.SZ):參股公司收到藥品GMP符合性檢查結果
格隆匯7月28日丨賽升藥業(300485.SZ)宣佈,近日,公司收到參股公司賽靈特藥品GMP符合性檢查結果(編號:浙2020第0013號)的通知。檢查範圍為治療用生物製品(豬源纖維蛋白粘合劑、原液車間、製劑車間),檢查時間為2020年6月10日-6月12日。
公司參股賽靈特是為了發揮產業協同效應。該次賽靈特申請並通過GMP符合性檢查表明其相關生產線符合《藥品生產質量管理規範(2010年修訂)》的要求,有利於賽靈特繼續保證產品質量和生產能力,從而滿足市場需求。該次通過GMP符合性檢查事項將不會對賽升藥業業績產生重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.